Findings on Drug Development Reported by Investigators at York University (The Interdependent Influence of Lobbying and Intellectual Capital On New Drug Development)

Prof. Vareska van der Vrande, Dr Patricia Klopf, and the Research Software Engineering and Consulting (RSEC) team at RSM are listed as funders for this article on pharmaceutical firms' resource allocation decision toward lobbying and other non-market activities, and their their new drug launches.

The research is published in an Elsevier publication Research Policy, 2024;53(2).

Information for this cutting came from https://www.newsrx.com/NewsRxWebsite/

Participants

  • Vareska van de Vrande
    Role: Faculty
    Reference type: Co-written by
  • Patricia Klopf
    Role: Faculty
    Reference type: Co-written by

Media Outlets

  • NewsRX Drugs and Therapies (Online)